CD20-directed Cytolytic Antibody [EPC]: Side Effects & Safety Data for 5 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
CD20-directed Cytolytic Antibody [EPC] includes 5 drugs with a combined 280,484 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
5
Drugs in Class
280,484
Combined Reports
All CD20-directed Cytolytic Antibody [EPC] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| RITUXIMAB | Rituxan | 178,614 | 28,910 | 54,631 | 16.2% |
| OCRELIZUMAB | OCREVUS | 56,186 | 1,406 | 10,364 | 2.5% |
| OFATUMUMAB | ARZERRA | 29,913 | 695 | 3,616 | 2.3% |
| OBINUTUZUMAB | Gazyva | 14,189 | 1,919 | 5,419 | 13.5% |
| UBLITUXIMAB | BRIUMVI | 1,582 | 27 | 213 | 1.7% |
Common Side Effects in CD20-directed Cytolytic Antibody [EPC] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Off label use | 43,743 | 6,527 |
| Drug ineffective | 35,713 | 3,259 |
| Fatigue | 26,905 | 2,535 |
| Pain | 22,561 | 2,143 |
| Covid-19 | 20,171 | 2,123 |
| Rheumatoid arthritis | 19,922 | 2,167 |
| Headache | 16,417 | 1,914 |
| Pyrexia | 16,076 | 2,229 |
| Infusion related reaction | 15,387 | 2,304 |
| Pneumonia | 14,722 | 3,473 |